Benzyl aminolevulinate

Drug Profile

Benzyl aminolevulinate

Alternative Names: 5-ALA benzylester; 5-ALA benzylesther; Benzvix

Latest Information Update: 15 Nov 2006

Price : $50

At a glance

  • Originator PhotoCure
  • Class Antineoplastics; Oxidants
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Gastrointestinal cancer

Most Recent Events

  • 15 Nov 2006 Discontinued - Preclinical for Gastrointestinal cancer in Europe (Topical)
  • 21 Apr 2005 Preclinical trials in Gastrointestinal cancer in Europe (Topical)
  • 14 May 2002 Clinical pilot trials in premalignant lesions of the gastrointestinal tract in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top